What compounds target MYLK?

BiohacksAI has identified 32 compounds that interact with MYLK (myosin light chain kinase). Top compounds include: nifedipine, ponatinib, ruxolitinib, pi 103, bosutinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MYLK (myosin light chain)?

MYLK is myosin light chain kinase. It is a molecular target for 32 compounds documented in PubMed bioassay data. UniProt ID: Q15746. NCBI Gene ID: 4638.

MYLK

MOLECULAR TARGET

myosin light chain kinase

UniProt: Q15746 NCBI Gene: 463832 compounds

MYLK (myosin light chain kinase) is targeted by 32 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MYLK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	nifedipine	5.34	208
2	ponatinib	4.26	70
3	ruxolitinib	4.23	68
4	pi 103	4.17	64
5	bosutinib	4.08	58
6	bi 2536	4.01	54
7	quizartinib	3.99	53
8	midostaurin	3.85	46
9	fasudil	3.66	38
10	nintedanib	3.61	36
11	tae 684	3.43	30
12	fedratinib	3.40	29
13	gilteritinib	3.40	29
14	dovitinib	3.09	21
15	jnj 7706621	3.09	21
16	lestaurtinib	3.04	20
17	ruboxistaurin	2.94	18
18	go 6976	2.89	17
19	r 406	2.83	16
20	k 252a	2.83	16
21	imd 0354	2.83	16
22	pha 665752	2.71	14
23	kw 2449	2.64	13
24	su 014813	2.20	8
25	rebastinib	2.20	8
26	cep 32496	1.95	6
27	bafetinib	1.95	6
28	tanzisertib	1.95	6
29	Wortmannin	1.39	3
30	myricetin-3-O-galactopyranoside [Supplementary Concept]	0.69	1
31	hydroxyfasudil [Supplementary Concept]	0.69	1
32	sp600125	0.69	1

About MYLK as a Drug Target

MYLK (myosin light chain kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 32 compounds with documented MYLK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MYLK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.